

CIRRICULUM VITAE
Jonathan C. King, M.D.

Personal History:

Santa Monica General Surgery
1304 15th Street, Suite 102
Santa Monica, CA 90404
(o) 310-319-4080
(f) 310-394-5215
joking@mednet.ucla.edu

Education:

B.S.-Biology: James Madison University, 1997-2001
M.D.: University of Maryland School of Medicine, 2002-2006
Internship: University of California Los Angeles Department of Surgery, 2006-2007
Residency: University of California Los Angeles Department of Surgery, 2007-2013
Fellowship: University of Pittsburgh Division of Surgical Oncology, 2013-2015

Licensure:

California: A112833; expiration 8/31/2017
DEA: FK4364737; expiration 12/31/2016

Board Certification:

American Board of Surgery: General Surgery 059346; expiration 12/31/2024
American Board of Surgery: Complex Surgical Oncology; Board Eligible

Professional Experience:

Present Position:

Assistant Professor of Surgery, Department of Surgery
David Geffen School of Medicine at UCLA, 2015-
Previous Positions:
Fellow, University of Pittsburgh Division of Surgical Oncology, 2013-2015
Resident University of California Los Angeles Department of Surgery, 2007-2013
Intern University of California Los Angeles Department of Surgery, 2006-2007

Professional Activities:

Society of Surgical Oncology (SSO)
American Hepato-Pancreaticobiliary Association (AHPBA)
American College of Surgeons (ACS)
Society of University Surgeons (SUS)
Alpha Omega Alpha (AOA)
JAMA-Archives of Surgery Scientific Reviewer: 2008-2009
American Medical Association-Medical Student Section (AMA-MSS) Secretary / Treasurer of
University of Maryland Chapter: 2003-2004

University of Maryland School of Medicine Office of Admissions Interviewer: 2003-2004

Honors and Special Awards:

Alpha Omega Alpha
Phi Kappa Phi
National Society of Collegiate Scholars
Omicron Delta Kappa
Golden Key National Honors Society

UCLA Department of Surgery Golden Scalpel Award for outstanding chief resident 2013
STAR Clinical Award 2010
Outstanding Student Teaching Award 2008, 2009
Longmire Surgical Society Annual Scientific Day 2009, 2010

Research Grants and Fellowships Received:

Society of University Surgeons-Wyeth Resident Clinical Award, Apigenin in Pancreatic Cancer; 2009-2010; \$15,000/year

Publication Bibliography:

A. Research Papers, Peer-Reviewed:

King J, Kazanjian K, Matsumoto J, Reber HA, Yeh M, Hines OJ. Distal pancreatectomy: Incidence of postoperative diabetes. *Journal of Gastrointestinal Surgery* 2008;12:1548-53.

King JC, Ng TT, White SC, Cortina G, Reber HA, Hines OJ. Pancreatic serous cystadenocarcinoma: A case report and review of the literature. *Journal of Gastrointestinal Surgery* 2009;13:1864-8.

King JC, Reber HA, Shiraga S, Hines OJ. Pancreatic-pleural fistula is best managed by early operative intervention. *Surgery* 2010;147:154-9.

Pham H, Chen M, Li A, **King J**, Angst E, Dawson D, Park J, Reber HA, Hines OJ, Eibl G. Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors. *Pancreas* 2010;39:332-9.

Li A, **King JC**, Moro A, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, Strieter RM, Burdick M, Go VVW, Reber HA, Eibl G, Hines OJ. Overexpression of CXCL5 is associated with poor survival of patients with pancreatic cancer. *Am J Pathol* 2011;178:1340-9.

King JC, Abeywardina S, Farrell JJ, Reber HA, Hines OJ. A modern review of the operative management of chronic pancreatitis. *American Surgeon* 2010;76:1071-4.

Takahashi H, Chen MC, Pham H, Angst E, **King JC**, Park J, Brovman EY, Ishiguro H, Harris DM, Reber HA, Hines OJ, Gukoyskaya AS, Go VL, Eibl G. Baicalein, a component of *Scutellaria baicalensis*, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. *BiochimBiophysActa* 2011;1813:1465-74.

King JC, Li A, Lu Q-Y, Li G, Moro A, Go VLW, Reber HA, Eibl G, Hines OJ. Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. *BiochimBiophysActa* 2012;1823:593-604.

Pham HT, Chen M, Takahashi H, **King J**, Reber HA, Hines OJ, Pandol S, Eibl G. Apigenin inhibits NNK-induced focal adhesion kinase activation in pancreatic cancer cells. *Pancreas* 2012;41:1306-15.

Angst E, Park JL, Moro A, Lu QU, Li G, **King J**, Chen M, Reber HA, Go VLW, Dawson DW, Eibl G, Hines OJ. The flavonoid quercetin inhibits pancreatic cancer growth *in vitro* and *in vivo*. *Pancreas* 2013;42:223-9.

B. Research Papers, Peer-Reviewed (In Press):

King JC, Zeh HJ III, Zureikat AH, Celebrezze J, Holtzman MP, Stang ML, Tsung A, Bartlett DL, Hogg ME. Safety in Numbers: Progressive Implementation of a Robotics Program in an Academic Surgical Oncology Practice. *Surgical Innovation* 2016.

C. Research Papers, Peer-Reviewed (Submitted):

King JC, Zenati M, Steve J, Winters SB, Bartlett DL, Zureikat AH, Zeh HJ III, Hogg ME. Deviations from Expected Treatment of Pancreatic Cancer in Octogenarians: Analysis of Patient and Surgeon Factors.

D. Research Papers, Non Peer-Reviewed: None

E. Research Papers, Non Peer-Reviewed (In Press): None

F. Research Papers, Non Peer-Reviewed (Submitted): None

Chapters:

King JC, Hines OJ. Palliative Therapy for Pancreatic Cancer, In: Cameron JL, ed. Current Surgical Therapy, 10th Edition. Amsterdam: Elsevier, 2010.

King JC, Hines OJ. Anatomy and Physiology of the Stomach. In: Yeo CJ, ed. Shackelford's Surgery of the Alimentary Tract, 7th Edition. Philadelphia: Saunders, 2013.

King JC, Hogg M, Zeh HJ III. Major Disruptions of Pancreaticojejunostomy. In: Pawlik, Merchant, Maithel, eds. Gastrointestinal Surgery: Management of Complex Perioperative Complications. Heidelberg: Springer, 2015.

Chapters (In Press):

King JC, Pingpank JF. Intraperitoneal Therapy of Gastrointestinal Cancers. In: Sun W, ed. Multidisciplinary Management of Gastrointestinal Cancers.

King JC, Zeh HJ III. Minimally Invasive Approaches to Cancer. In: Zinner MJ, Ashley SW, eds. Maingot's Abdominal Operations, 13th Edition. New York: McGraw-Hill.

Letters to the Editor:

King JC, Reber HA, Hines OJ. Response to: "Endoscopic therapy as a first line therapy for pancreatic-pleural fistula." Surgery 2010;148:609-10.

King JC, Hines OJ. Predicting exocrine insufficiency following pancreatic resection. Journal of Surgical Research 2010;164:e43-5.

Reviews: None

Editorials: None

Papers in Preparation (Research Completed): None

Abstracts:

Li A, **King JC**, Eibl G, Sugi M, Streiter RM, Moro A, Reber HA, Hines OJ. Dual inhibition of CXCR2 and VEGFR2 blocks pancreatic cancer growth. [Oral presentation: 2/3/2009; Academic Surgical Congress; Ft. Meyer's Beach, FL].

Pham H, Li A, Chen M, **King J**, Angst E, Park J, Dawson D, Reber HA, Hines OJ, Eibl G. Loss of 15-hydroxyprostaglandin dehydrogenase contributes to increased

prostaglandin E2 in pancreatic tumors. [Poster presentation: 4/21/2009; American Association for Cancer Research; Denver, CO].

King JC, Reber HA, Eibl G, Li A, Angst E, Hines OJ. A comparison of laparoscopic and open distal pancreatectomy. [Poster presentation: 6/3/2009; Society for Surgery of the Alimentary Tract, Chicago, IL].

Li A, **King JC**, Sugi M, Strieter RM, Burdick MD, Reber HA, Eibl G, Hines OJ. CXCL5[ENA-78] is overexpressed in pancreatic cancer and mediates pancreatic cancer-derived angiogenesis. [Poster presentation: 6/1/2009; Digestive Disease Week 2009, Chicago, IL].

King JC, Li A, Sugi M, Dawson D, Eibl G, Reber HA, Hines OJ. CXCL5 expression heralds a worse prognosis for pancreatic cancer patients. [Oral presentation: 10/14/2009; American College of Surgeons Clinical Congress; Chicago, IL].

Li A, **King J**, Moro A, Sugi M, Dawson DW, Kaplan J, Li G, Lu X, Go VLW, Reber HA, Eibl G, Hines OJ. CXCL5 correlates with survival and mediates pancreatic cancer growth. [Poster presentation: 11/5/09; American Pancreatic Association; Honolulu, HI].

King JC, Abeywardina S, Farrell JJ, Reber HA, Hines OJ. A modern review of the operative management of chronic pancreatitis. [Oral presentation, plenary session: 1/22/10; Southern California Chapter of the American College of Surgeons; Santa Barbara, CA].

King JC, Li A, Reber HA, Go VW, Eibl G, Hines OJ. Apigenin induces pancreatic cancer cell apoptosis via a p53-mediated mechanism. [Oral 'quick-shot' presentation: 2/5/10; Academic Surgical Congress; San Antonio, TX].

Angst E, Park J, Moro A, Lu Q-Y, **King JC**, Go VLW, Reber HA, Eible G, Hines OJ. Quercetin inhibits growth of pancreatic cancer in vitro and in vivo. [Poster presentation: 4/20/10; American Association of Cancer Research; Washington, DC].

Pham HT, Chen M, **King JC**, Takahashi H, Pandol S, Reber HA, Hines OJ, Eibl G. Apigenin inhibits NNK-induced FAK Y397 activation in pancreatic cells. [Poster presentation: 5/5/10; Digestive Disease Week; New Orleans, LA].

King JC, Lu QY, Zhang L, Li G, Moro A, Reber HA, Go VLW, Eibl G, Hines OJ. Apigenin induces pancreatic cancer apoptosis via p53 and PUMA. [Poster presentation: 11/3/10; American Pancreatic Association; Chicago, IL].

King JC, Li A, Reber HA, Eibl G, Hines OJ. CXCL5-Mediated signaling events and *in vitro* angiogenesis in human pancreatic cancer. [Oral presentation: 2/2/11; Academic Surgical Congress; Huntington Beach, CA].

King JC, Lu QY, Li G, Moro A, Takahashi H, Chen M, Go VLW, Reber HA, Eibl G, Hines OJ. The dietary flavonoid apigenin inhibits growth and induces apoptosis in pancreatic cancer. [Poster presentation: 5/19/12; Pancreas Club; San Diego, CA].

King JC, Steve J, Zenati M, Winters S, Bartlett DL, Zureikat A, Zeh HJ III, Hogg ME. Age bias and under-treatment in octogenarians with pancreatic cancer. [Poster presentation: 3/26/15; Society of Surgical Oncology; Houston, TX; 5/15/15; Pancreas Club; Washington, D.C.].

King JC, Zeh HJ III, Zureikat A, Stang MT, Bartlett DL, Hogg ME. Implementation of a surgical oncology robotic program: Safe with progressive improvement, expansion, and growth. [Poster presentation: 3/26/15; Society of Surgical Oncology; Houston, TX].

Girgis MD, Zenati MS, Steve J, **King J**, Novak S, Winters SB, Bartlett DL, Zureikat A, Zeh HJ, Hogg ME. Long term oncologic outcomes after robotic resection are not inferior to open for pancreatic cancer. [Oral presentation: 5/15/15; Pancreas Club; San Diego, CA].